Vertex Pharmaceuticals Incorporated(VRTX) Stock Research - Grey Stern Research

Vertex Pharmaceuticals Incorporated (VRTX) Stock Analysis

$456.97 (-1.88%)

VRTX Financial Performance


Use the table below to view Vertex Pharmaceuticals Incorporated's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $465.73 -
52 Week Low $347.51 -
52 Week High $519.88 -
Market Cap $119.9 Billion 1/21
Gross Margin 86% 11/21
Profit Margin 38% 2/21
EBITDA margin 40% 1/21
Q3 - 2024 Revenue $2.8 Billion 3/21
Q3 - 2024 Earnings $1.0 Billion 3/21
Q3 - 2024 Free Cash Flow $1.5 Billion 2/21
Trailing 4 Quarters Revenue $10.6 Billion 3/21
Trailing 4 Quarters Earnings -$479.8 Million 15/21
Quarterly Earnings Growth 1% 11/21
Annual Earnings Growth -113% 20/21
Quarterly Revenue Growth 12% 9/21
Annual Revenue Growth 7% 12/21
Cash On Hand $5.2 Billion 3/21
Short Term Debt $0 16/21
Long Term Debt $1.7 Billion 3/21

Vertex Pharmaceuticals Incorporated Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Vertex Pharmaceuticals Incorporated's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 5/21
PS 11.30 10/21
PB 7.67 7/21
PC 22.89 8/21
Liabilities to Equity 0.42 8/21
ROA -0.02 5/21
ROE -0.03 6/21
Current Ratio 3.36 12/21
Quick Ratio 0.99 14/21
Long Term Debt to Equity 0.11 10/21
Debt to Equity 0.11 10/21
Burn Rate -5.36 18/21
Cash to Cap 0.04 14/21
CCR 1.43 4/21
EV to EBITDA 104.28 3/21
EV to Revenue 10.97 10/21

Company Details

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

CEO: Dr. Jeffrey Leiden

Website: https://www.vrtx.com

Address: 50 Northern Ave Boston, MASSACHUSETTS

Exchange: NASDAQ Global Select

Industry: Biotechnology

Vertex Pharmaceuticals Incorporated Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Vertex Pharmaceuticals Incorporated. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Alnylam Pharmaceuticals, Inc. ALNY $32.5 Billion
BioMarin Pharmaceutical Inc. BMRN $12.0 Billion
Regeneron Pharmaceuticals, Inc. REGN $81.0 Billion
Viking Therapeutics, Inc. VKTX $5.6 Billion
Reata Pharmaceuticals, Inc. RETA $6.6 Billion
Sarepta Therapeutics, Inc. SRPT $12.0 Billion
Seagen Inc. SGEN $43.2 Billion
Intercept Pharmaceuticals, Inc. ICPT $794.7 Million
Madrigal Pharmaceuticals, Inc. MDGL $7.0 Billion
PTC Therapeutics, Inc. PTCT $3.9 Billion
Editas Medicine, Inc. EDIT $163.4 Million
Intellia Therapeutics, Inc. NTLA $1.5 Billion
CRISPR Therapeutics AG CRSP $4.4 Billion
Krystal Biotech, Inc. KRYS $5.3 Billion
Moderna, Inc. MRNA $16.4 Billion
Beam Therapeutics Inc. BEAM $2.2 Billion
BioNTech SE BNTX $27.7 Billion
Caribou Biosciences, Inc. CRBU $196.5 Million
Verve Therapeutics, Inc. VERV $593.5 Million
Ginkgo Bioworks Holdings, Inc. DNA $559.3 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
VRTX Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 2.8 Billion $1.0 Billion
Q2 2024 $ 2.6 Billion -$3.6 Billion
Q1 2024 $ 2.7 Billion $1.1 Billion
Q4 2023 $ 2.5 Billion $968.8 Million
Q3 2023 $ 2.5 Billion $1.0 Billion
Q2 2023 $ 2.5 Billion $915.7 Million
Q1 2023 $ 2.4 Billion $699.8 Million
Q4 2022 $ 2.3 Billion $818.9 Million

View All

VRTX Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $5.2 Billion $22.2 Billion $1.7 Billion $15.6 Billion
Q2 2024 $4.6 Billion $20.1 Billion $933.4 Million $14.8 Billion
Q1 2024 $9.2 Billion $23.9 Billion $721.3 Million $18.5 Billion
Q4 2023 $10.4 Billion $22.7 Billion $808.4 Million $17.6 Billion
Q3 2023 $0 $21.7 Billion $744.7 Million $21.7 Billion
Q2 2023 $10.2 Billion $20.3 Billion $767.6 Million $15.5 Billion
Q1 2023 $9.3 Billion $19.0 Billion $789.2 Million $14.4 Billion
Q4 2022 $10.5 Billion $18.2 Billion $561.0 Million $13.9 Billion

View All

VRTX Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 $1.5 Billion $120.0 Million $668.0 Million
Q2 2024 -$3.8 Billion -$76.7 Million -$4.6 Billion
Q1 2024 $1.1 Billion -$248.4 Million -$1.2 Billion
Q4 2023 $118.5 Million -$116.1 Million -$744.3 Million
Q3 2023 $0 $0 $0
Q2 2023 $915.7 Million $0 $915.7 Million
Q1 2023 $857.8 Million -$42.1 Million -$1.2 Billion
Q4 2022 $1.0 Billion -$33.6 Million $1.3 Billion

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions